LitCovid-sample-Enju  

PMC:7228307 / 60295-60638 JSONTXT 5 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T455 0-6 JJ denotes Future
T456 7-17 NNS denotes directions
T457 18-20 IN denotes in
T458 21-24 DT denotes the
T459 25-36 NN denotes development
T460 37-40 CC denotes and
T461 41-44 NN denotes use
T462 45-47 IN denotes of
T463 48-59 JJ denotes therapeutic
T464 60-70 NNS denotes antibodies
T465 71-77 MD denotes should
T466 78-90 RB denotes increasingly
T467 91-96 VB denotes mimic
T468 97-103 JJ denotes normal
T469 104-114 JJ denotes protective
T470 115-123 NN denotes antibody
T471 124-133 NNS denotes responses
T472 133-134 -COMMA- denotes ,
T473 135-140 WDT denotes which
T474 141-144 VBP denotes are
T475 145-155 JJ denotes polyclonal
T476 156-159 CC denotes and
T477 160-168 VBN denotes elicited
T478 169-171 IN denotes in
T479 172-175 DT denotes the
T480 176-183 NN denotes context
T481 184-186 IN denotes of
T482 187-193 JJ denotes innate
T483 194-202 NN denotes receptor
T484 203-213 NN denotes engagement
T485 214-219 WDT denotes which
T486 220-228 VBZ denotes includes
T487 229-232 DT denotes the
T488 233-236 NNS denotes FcR
T489 237-239 RB denotes as
T490 240-244 RB denotes well
T491 245-247 IN denotes as
T492 248-253 JJ denotes other
T493 254-264 RB denotes powerfully
T494 265-275 JJ denotes responsive
T495 276-283 NNS denotes systems
T496 284-293 VBG denotes including
T497 294-297 DT denotes the
T498 298-307 JJ denotes Toll‐like
T499 308-317 NNS denotes receptors
T500 318-321 CC denotes and
T501 322-332 NN denotes complement
T502 333-342 NNS denotes receptors
R467 T456 T455 arg1Of directions,Future
R468 T456 T457 arg1Of directions,in
R469 T460 T457 arg2Of and,in
R470 T460 T458 arg1Of and,the
R471 T459 T460 arg1Of development,and
R472 T461 T460 arg2Of use,and
R473 T460 T462 arg1Of and,of
R474 T464 T462 arg2Of antibodies,of
R475 T464 T463 arg1Of antibodies,therapeutic
R476 T456 T465 arg1Of directions,should
R477 T467 T465 arg2Of mimic,should
R478 T467 T466 arg1Of mimic,increasingly
R479 T456 T467 arg1Of directions,mimic
R480 T471 T467 arg2Of responses,mimic
R481 T471 T468 arg1Of responses,normal
R482 T471 T469 arg1Of responses,protective
R483 T471 T470 arg1Of responses,antibody
R484 T471 T472 arg1Of responses,","
R485 T471 T473 arg1Of responses,which
R486 T471 T474 arg1Of responses,are
R487 T476 T474 arg2Of and,are
R488 T471 T475 arg1Of responses,polyclonal
R489 T475 T476 arg1Of polyclonal,and
R490 T477 T476 arg2Of elicited,and
R491 T471 T477 arg2Of responses,elicited
R492 T477 T478 arg1Of elicited,in
R493 T480 T478 arg2Of context,in
R494 T480 T479 arg1Of context,the
R495 T480 T481 arg1Of context,of
R496 T484 T481 arg2Of engagement,of
R497 T484 T482 arg1Of engagement,innate
R498 T484 T483 arg1Of engagement,receptor
R499 T480 T485 arg1Of context,which
R500 T480 T486 arg1Of context,includes
R501 T491 T486 arg2Of as,includes
R502 T491 T487 arg1Of as,the
R503 T491 T489 arg1Of as,as
R504 T491 T490 arg1Of as,well
R505 T488 T491 arg1Of FcR,as
R506 T495 T491 arg2Of systems,as
R507 T495 T492 arg1Of systems,other
R508 T495 T493 arg1Of systems,powerfully
R509 T495 T494 arg1Of systems,responsive
R510 T495 T496 arg1Of systems,including
R511 T500 T496 arg2Of and,including
R512 T500 T497 arg1Of and,the
R513 T499 T498 arg1Of receptors,Toll‐like
R514 T499 T500 arg1Of receptors,and
R515 T502 T500 arg2Of receptors,and
R516 T502 T501 arg1Of receptors,complement